Prostate Cancer Advances at ESMO25 with Tian Zhang @tiansterzhangmd.bsky.social @myesmo.bsky.social oncodaily.com/voices/prost... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025 #ProstateCancer

ESMO 2025 - The Grand Catch-Up (Berlin, October 17-21, 2025) @myesmo.bsky.social @ptarantinomd.bsky.social @erikahamilton9.bsky.social @stephenvliu.bsky.social @arndtvogel.bsky.social @tiansterzhangmd.bsky.social oncodaily.com/blog/esmo-20... #OncoDaily #Oncology #Cancer #ESMO #ESMO25 #ESMO2025

Glad to be an #ESMOAmbassador during #ESMO25 in Berlin! Here to learn the latest data for our patients and share ideas to improve future outcomes. See you in Berlin! @oncoalert.bsky.social

Great Editorial Led by Nicolas Sayegh on Subsets of Prostate Cancer - Tian Zhang @tiansterzhangmd.bsky.social oncodaily.com/insight/nico... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ProstateCancer

🎥Results from PDIGREE: ipi + nivo in mccRCC shows consistent safety & early CRs in a diverse U.S. population @tiansterzhangmd.bsky.social shares insights from #ASCO25 ➡️https://buff.ly/o2oUojf⬅️ @ASCO #kcsm #UroOnc #UroSoMe #CTSM #TrialUpdate #ImmunoOnc

#ShahneenSandhu on collaborative efforts with industry partners - how do we maximize time & effort to make industry supported IITs and large phase 3 trials for clinical development. @anzuptrials.bsky.social #ANZUP25

@profiand.bsky.social with key insights to large trial and grant funding in Australia — trial impact, equity in diverse populations, cost effectiveness, patient advocate/consumer involvement, and feasibility @anzuptrials.bsky.social #ANZUP25

Great kickoff to clinical trials workshop #ANZUP25 — #MelissaLeMesurier w patient perspective and #ChrisGianacas biostats on collaborative efforts for clinical trials. Same global themes for clinical trial development. @anzuptrials.bsky.social @craiggedye.bsky.social @profiand.bsky.social

Pleasure to highlight your work with #UroToday @ravimadan.bsky.social - as we all consider how best to treat PSMA avid disease.

Proud of our #UTSWcancer clinical research teams displaying our cancer center’s ongoing work in clinical trials @aacicancer.bsky.social #CRI25 meeting today! Clinical trials are essential to improving outcomes for our patients with cancer - here to network & learn best practices!

I categorically refuse to accept either of these as normal or routine. www.nytimes.com/2025/06/14/u...

See our #Urotoday recording with David Wise on this promising trial in #prostatecancer reported at #ASCO25! urldefense.com/v3/__https:/...

New from #ASCO25: Final results of CheckMate-214 show that nivo + ipi continues to improve OS compared with sunitinib for previously untreated advanced RCC: dailynews.ascopubs.org/do/checkmate... #ASCODailyNews @mskcancercenter.bsky.social @tiansterzhangmd.bsky.social

Traveling w/ mixed emotions to @asco #asco25 this yr. Celebrating science & the yrs of dedication, work, & patient contributions to cancer clinical trials. But science itself is under attack — defunding of preclinical discovery work will end up slowing our clinical advances. 1/n

Our hearts go out to the Biden family. Metastatic prostate cancer is common but hard. They will face many treatment decisions ahead. apple.news/Ai-QLq9onRNW...

Women in RCC Negotiations Spotlight at IKCSEU25 - Tian Zhang @tiansterzhangmd.bsky.social @drnataliagandur.bsky.social @kidney-cancer.bsky.social oncodaily.com/blog/tian-zh... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IKCSEU25 #RCC #IKCS25 #WomenInRCC

Plenary session with @MarcelaMaus @MGHCancerCenter on future CAR-T cells — setting vision toward personalized, patient centered approaches to find the right CARTs. #AACR25 @oncoalert.bsky.social @theaacr.bsky.social

Hey all my #Cansky and especially #Kidneycancer folks, check out this awesome episode from @lauraesfeller.bsky.social and Judy Nicholson Foundation featuring @tiansterzhangmd.bsky.social. Fantastic episode👏🏻👏🏻. youtu.be/25TXzH5suio?...

A great start to #UTChrisWood25 - localized RCC discussions from diagnosis (ccRCC score) & novel tracers to treatment of surgery, SBRT, & ablation. #IvanPedrosa #ChadTang #JoseKaram #IsamuTachibana #mohamedabdelsalam & interactive panel discussion!

Best practices for second line treatment in Metastatic Urothelial Carcinoma - @tiansterzhangmd.bsky.social .bsky.social oncodaily.com/url/267046 #GUOnc #UrothelialCarcinoma #Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer

@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25

#MattGalsky updating results of #NIAGARA - great to see pathologic complete responses from neoadj gem-cis-durvalumab — durva improves disease free & overall survival even in those w pathCR. @ascocancer.bsky.social #GU25

#MattMilowsky with updated #Checkmate274 trial - adjuvant nivolumab after cystectomy improves time to recurrence & overall survival in #bladdercancer. Sets up ongoing #Alliance #MODERN trial! @ascocancer.bsky.social #GU25

Mevrometostat with enzalutamide vs enza alone with nice PSA responses and good PFS benefit! @ascocancer.bsky.social #GU25

#TanyaDorff w always thoughtful w discussion for metastatic #prostatecancer — buckets of treatments - doublets, triplets, XRT, including trials! #TRIPLESWITCH, #ADREAM, S1802, & more! @ascocancer.bsky.social #GU25

#EdwinPosadasMD with eloquent discussion on prostatectomy vs surgery, importance of the #PORTOS biomarker to help define radiation benefit. @ascocancer.bsky.social #GU25

#NeerajAggarwal presents final overall survival from #TALAPRO2 trial - patients w metastatic #prostatecancer lived longer and had improved time to chemo. Only 2 MDS/AML events in entire trial. Supporting the talazoparib-enzalutamide approval. #GU25 @ascocancer.bsky.social

George Zhao presents PORTOS score and modeling radiation outcomes. Important to help select patients likely to benefit from XRT. @ascocancer.bsky.social #GU25

Tribute to @felixfengmd - Feng Symposium kicks off w @HimanshuNagarMD @mishabeltran @ASCO President-elect #EricSmall at the helm. Announcing the endowed @ASCO YIA, fostering future scientists and science in #prostatecancer. We miss you Felix. Love to @MaryFengMD & family today.

Our latest paper on circulating immune biomarkers for metastatic kidney cancer - Tian Zhang @tiansterzhangmd.bsky.social oncodaily.com/insight/tian... #KidneyCancer #OncoDaily #Oncology #Medicine #Health #Cancer

#UTSouthwestern #SimmonsCancerCenter raising community awareness for #prostatecancer this AM - screening “The Silent Killer: Prostate Cancer in the AA Community” — packed room at Light of the World church. Thanks Director #LandiMaduro for coming! m.imdb.com/title/tt3437...

At #AUC3 this A.M. discussing what’s next for treatment of NMIBC and treatment of variant histology UC - Gopa Iyer and Josh Meeks chairing session this AM with talks from Andrea Necchi, Michiel Van der Heijden, and Roger Li #bladdercancer

This GU oncology family — wonderful first #AUC3 consensus conference! @drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social

Creating a bladder & kidney cancer starter pack of friends and colleagues here in @bsky.app! Please comment if you want to be added! bsky.app/start/did:pl... @pgrivasmdphd.bsky.social @drchoueiri.bsky.social @erplimackmd.bsky.social @davidaggen.bsky.social @pcvblack.bsky.social

Awesome panel moderated by #MontyPal #BradMcGregor for non clear cell #Kidneycancer. Histology matters! And so do molecular markers! #AUC3 @drchoueiri.bsky.social @pgrivasmdphd.bsky.social @davidaggen.bsky.social @erplimackmd.bsky.social

#BrianRini & #MikeAtkins debate refractory #kidneycancer management after IO front line or adjuvant PD1 inhibitor. Do we rechallenge? Yes likely after a certain time point (6 vs 12 months debated). #AUC3

Drs. #NaomiHaas #HansHammers debate locally advanced #kidneycancer and use of periop immunotherapy. Grading, staging, and prediction of risk/benefit leads to rigorous shared decision making with our patients. @drchoueiri.bsky.social #AUC3

Temporary halt or are we witnessing the start of an anti-science movement? I hope only temporary. Science and medicine and the search for truth are fundamental to helping our patients live longer.

#BrianShuch kicks us off, local #kidneycancer heterogeneous - guppies, goldfish and sharks! Integrating staging & biomarkers to help us evaluate risk and prognosis. #AUC3

Launching #AUC3 in Miami, consensus across kidney and bladder cancers. From small steps to significant scientific advances that change our patients’ lives. @drchoueiri.bsky.social #MontyPal #RanaMcKay #JonathanRosenberg

This Christmas and every year I remember my current and past patients with ornaments on our tree. Have been fortunate to care for thousands in my ten year career in oncology. Hope to help thousands more in the years to come. 🎄🕯️

Huge kudos to the NCCN for officially incorporating prostate cancer into the Genetic/Familial High-Risk Assessment Guidelines. We've come a long way!

Redefining first-line options for advanced urothelial carcinoma! Insights on platinum chemotherapy, immunotherapy combos, and patient-tailored strategies. @tiansterzhangmd.bsky.social @oncoalert.bsky.social @oncbrothers.bsky.social #Oncology #BladderCancer

From @utswinternalmed.bsky.social CME to #GrandRoundsinUrology in the same day! #YairLotan discussed #bladdercancer biomarkers & #ShilpaGupta on sequential treatments in metastatic disease.

Super charged CME event @utswinternalmed.bsky.social #UTSWCancer #YearinReview 2024! Awesome turnout. Was pleased to highlight all the updates in #kidneycancer #bladdercancer in 15 mins!

Thanks for highlighting @oncodaily.bsky.social! Was special to do this w my friend from fellowship @erikahamilton9.bsky.social and appreciate the @oncbrothers.bsky.social for hosting us!!

Working on our #ASCO abstracts already. Deadline Jan 28th! No doubt will be another wave of clinical oncology progress at the annual meeting in 2025!

@smreddymd.bsky.social highlights immunotherapy for #breastcancer at @utswinternalmed.bsky.social grand rounds. Our #UTSWCancer breast cancer team is strong!

#Prostatecancer starter pack! Thanks for creating it @ravimadan.bsky.social & including me! Totally here for the prostate cancer knowledge & networks.

New here — always in search of a challenge and blue skies. Loved the #MedTwitter/#OncTwitter community and hoping the #MedBlueSkies community will be just as good!